PEG-asparaginase (Q36909298)

17 August 2017

1 reference

title

PEG-asparaginase. (English)

1 reference

17 August 2017

Cecilia H Fu

1

1 reference

PubMed ID

17696798

17 August 2017

Kathleen M Sakamoto

series ordinal

2

1 reference

PubMed ID

17696798

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

12

1 reference

17 August 2017

1977-1984

1 reference

An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Antitumor enzyme: polyethylene glycol-modified asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

High efficacy of monomethoxypolyethylene glycolconjugated l-asparaginase (PEG2-ASP) in two patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Pegaspargase-induced pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1977

10.1517/14656566.8.12.1977

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17696798